Zycus Named a LEADER in Supplier Value Management Platforms by Independent Research Firm
17.9.2024 18:00:00 EEST | Business Wire | Press release
Zycus, a leading provider of GenAI-powered Source-to-Pay solutions, today announced that it has been recognized as a Leader in The Forrester Wave™: Supplier Value Management (SVM) Platforms, Q3 2024. We believe Zycus’ position as a leader in this prestigious report highlights its commitment to innovation and customer success.
The 9 vendors evaluated were rated on 33 criteria covering current offering, strategy, and market presence with Zycus receiving the top score in the strategy category. Zycus also received the highest possible score in 10 criteria including Vision and Innovation.
The report specifically notes:
- “Zycus uses its exceptional understanding of customer demand to offer a comprehensive SVM suite with a strong go-to-market approach and vision.”
- “Zycus has a compelling vision for the SVM space, and its innovation and strategy tie into this, allowing it to win new clients.”
“Zycus is an ideal partner for organizations seeking an SVM platform that emphasizes product innovation and demonstrates strong customer centricity,” states the report authored by Forrester Senior Analyst, Jeffrey Rajamani.
Forrester’s recognition comes on the heels of Zycus’ success in creating the world’s first GenAI-powered SVM Solution Suite.
"Being named a Leader in the Forrester Wave™ for SVM Platforms is, for us, a testament to our innovation and dedication to meeting customer needs over 2 decades," said Aatish Dedhia, Founder & CEO of Zycus. "Our vision for the future of procurement is to continuously evolve and enhance our solutions through cutting-edge GenAI capabilities."
For more information on Zycus’ Supplier Value Management Suite and its position in the Forrester Wave™, click here.
About Zycus:
Zycus is the leader in Source-to-Pay (S2P) solutions, pioneering the world’s first Generative AI (GenAI) powered platform that helps procurement achieve 10X speed and efficiency. It has been a trusted partner of choice for large global enterprises for over two decades and is consistently recognized by leading industry analysts for its organically built, composable and extensible source-to-pay suite.
Its Merlin GenAI Suite automates tactical tasks, empowering procurement teams to focus on strategic initiatives. Additionally, it offers one-of-its-kind conversational AI, Merlin Assist, for business users, integrated with Microsoft Teams to streamline intake management with a user-friendly experience.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240917321370/en/
Contacts
Arnish Shah
Associate Director – Marketing
arnish.shah@zycus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom